About Romark Global Pharma
Romark Global Pharma is a is a pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases and cancers. The Company markets Alinia (nitazoxanide) tablets, 500 mg in the United States through a specialty sales force focused on gastroenterologists and primary care physicians.
Missing: Romark Global Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Romark Global Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Romark Global Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Romark Global Pharma is included in 2 Expert Collections, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Romark Global Pharma Patents
Romark Global Pharma has filed 1 patent.
Dosage forms, Cyclopropanes, Drug delivery devices, Pharmacokinetics, Carbamates
Dosage forms, Cyclopropanes, Drug delivery devices, Pharmacokinetics, Carbamates
Latest Romark Global Pharma News
Feb 4, 2016
- Research and Markets 02/04/2016 | 11:12am US/Eastern (You can enter multiple email addresses separated by commas) Message : *Required fields Research and Markets ( http://www.researchandmarkets.com/research/qh96g2/cryptosporidiosis ) has announced the addition of the "Cryptosporidiosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cryptosporidiosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cryptosporidiosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered:
Romark Global Pharma Web Traffic
Romark Global Pharma Rank
Romark Global Pharma Frequently Asked Questions (FAQ)
When was Romark Global Pharma founded?
Romark Global Pharma was founded in 1993.
Where is Romark Global Pharma's headquarters?
Romark Global Pharma's headquarters is located at 3000 Bayport Drive, Tampa.
What is Romark Global Pharma's latest funding round?
Romark Global Pharma's latest funding round is Debt - II.
How much did Romark Global Pharma raise?
Romark Global Pharma raised a total of $189.29M.
Who are the investors of Romark Global Pharma?
Investors of Romark Global Pharma include The D. E. Shaw Group.
Who are Romark Global Pharma's competitors?
Competitors of Romark Global Pharma include ViaCyte, Five Prime Therapeutics, IRX Therapeutics, GettingHired, Trana Discovery and 10 more.
Compare Romark Global Pharma to Competitors
Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.
Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.
Acucela Inc. is a biotech company discovering drug therapies for eye diseases. Neurodegenerative retinal diseases such as macular degeneration, Stargardt's disease, retinitis pigmentosa and glaucoma, affect quality of life for over 50 million people worldwide per the company.
is discovering compounds that selectively inhibit replication of the hepatitis C virus, and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. They aim to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate.
Lycera is a biopharmaceutical company pioneering approaches to the discovery and development of oral medicines for treating autoimmune diseases. The company is targeting pathways to develop new classes of selective, oral immunomodulators for the treatment of patients with diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera's goal is to develop drug candidates with efficacy and safety profiles that change the treatment paradigm for patients with autoimmune diseases. Based on preclinical studies, the company's emerging drug candidates demonstrate improved oral efficacy and/or safety compared to the current standard-of-care antiproliferative and immunosuppressive agents.
Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.